Alterations in MAP2 expression and distribution are often observed in various neurodegenerative diseases. For example, in Alzheimer's disease, there is a loss of MAP2 in affected neurons, which correlates with dendritic degeneration and synaptic loss. Studying these changes can help in understanding the pathophysiology of such diseases and potentially aid in the development of therapeutic strategies.
